HALIFAX, Nova Scotia, January 29, 2021 (GLOBE NEWSWIRE) – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of neutral antibodies against SARS- CoV-2 virus. These antibodies bind to the specific parts of the virus, reducing viral infection and potentially protecting the patient from poor COVID-19 symptom presentation or SARS-CoV-2 reabsorption in the future. future. Not all antibodies can prevent the virus from infecting the patient, and, according to recent reports, the levels of neutral antibodies are fluctuating, such as that as the strength of the antibody defense. Once widely tested, MedMira’s neutralizing antibody test can effectively identify the antibodies with the inhibitory potential, thus, potentially, a powerful tool for qualitative assessment of antibody status before and after vaccination, as well as providing insights into a person’s immunity. to SARS-CoV-2. At this time, there is no guarantee that this product will meet the regulatory requirements and subsequently receive regulatory approval..
“Over the past twenty years, our Research and Development group has been instrumental in developing the innovative diagnostic solutions, which have allowed us to rapidly transform our RVF.® platform and develop this neutralizing antibody test prototype that will significantly enhance the conventional serology assessments, incorporating our current REVEALCOVID-19 ™ PLUS Total Antibody Test, ”said Hermes Chan, CEO of MedMira. “For example, a positive antibody test shows that you have antibodies in general, and a positive antibody neutralizing test could tell you how effective these antibodies are. This is another milestone in the expansion of our COVID-19 product family, and we are excited about the future. ”
MedMira is committed to offering a range of high quality COVID-19 products to address various global market needs and reflect on the scientific developments. A regulatory update as well as the latest product development strategy will be announced publicly shortly.
About MedMira
MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. Company Trials provides hospitals, laboratories, clinics, and individuals with immediate disease diagnoses, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold worldwide under Reveal®, Multiplo® and Miriad® logos. Based on the Patented Vertical Flow® Technologically, MedMira’s rapid HIV test is the only one in the world to have received regulatory approval in Canada, the United States, China and the European Union. MedMira has corporate offices and manufacturing facilities in Halifax, Nova Scotia, Canada. For more information, visit medmira.com. Follow us on Twitter and LinkedIn.
This press release is in progress–look at statements, which involve risk and uncertainty and reflect the Company’s current expectations of future events, including statements in terms of potential regulatory approval, product launch, future growth, and new business opportunities. Actual events may differ materially from those predicted here and may depend on a number of factors including, but not limited to, changes in circumstances. market, successful and timely completion of clinical studies, uncertainty associated with the regulatory consent process, the establishment of corporate alliances and other risks. detailed from time to time in the company quarterly films.
Neither TSX Venture Exchange nor its regulatory services provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the suitability or accuracy of this press release.
Contact MedMira
Markus Meile
Chief Financial Officer
MedMira Inc.
[email protected]
